Safety and Performance Assessment of the Decongestant Seawater Spray Pocket Valve Enriched With Essential Oils in Patients With Acute Rhinitis Associated With Nasal Obstruction

Inclusion Criteria:

• 1. Patient ≥ 12 years.
• 2. Patient with acute rhinitis associated with nasal obstruction during infectiousepisodes such as rhinopharyngitis (cold), rhinosinusitis, or during non-infectiousepisodes such as allergic rhinitis.
• 3. a. Informed adult patient who has given written consent prior to any study specificprocedure. b. Informed minor patient who has given assent and whose legal guardianshave given written consent prior to any study-specific procedure.
• 4. Patient able to meet the study requirements for monitoring, spray use, andquestionnaire completion.
• 5. Patient affiliated to a social security scheme.

Exclusion Criteria:

• 1. Pregnant and/or breastfeeding woman
• 2. Hypersensitivity to seawater and/or known allergies to any of the ingredients ofthe spray.
• 3. Diseases causing narrowing of the airways (e.g. asthma, chronic obstructivepulmonary disease (COPD)) and/or respiratory insufficiency.
• 4. Patients with chronic nasal obstruction.
• 5. Patients on local and systemic vasoconstrictors, local and systemic corticosteroidsand antihistamines, non-steroidal anti-inflammatory drugs (NSAIDs), antibiotics andlocal antiseptics.
• 6. Concomitant use of other nasal sprays, essential oils for local nasal use, nasalcreams or gels.
• 7. Patients under guardianship, curatorship or safeguard of justice.